just picked this from ihub a great post Anthony from

New Post Public Reply Private Reply Replies (1) Message Board
crazyjogger925
1,265
just picked this from ihub a great post


Anthony from yahoo forum posted the comment below. The frontline doctor has the same sentiment as my friend ER doc.

"I am pretty confident I have talked to more front line docs and advanced practice providers who are in the middle of treating these patients, and I have as hell talked to more than Adam FF. Below are pasted emails from a doc on the east coast who's been in the middle of this and who has a huge social media following. He says the same thing every single provider I've talked to: Rem is NOT working. Maybe just maybe that's what it's stock has not done anything despite the massive hype.
Here is the first email:
Hi Anthony,
Thanks for the message. I have learned not to follow anyone and do the research myself. I am almost done with a MBA in healthcare management at University of Mass so I have been learning how to analyze things for myself. But most importantly, I am hoping my medical background can help me objectively look at the data and see what works or doesn’t.
Leronlimab is not some miracle drug but it is going to be more effective than remdesivir and HCQ. I have raw data from ICUs at a few hospitals in the northeast US. It is a national tragedy to see our physicians stop critically thinking and throw something against the wall and hoping it would stick.
I am doing my best getting Leronlimab out in my physician circles. I am unconventional physician, very conservative in my management of patients but aggressive when I need to. I believe in proactive medicine, not reactive medicine like a majority of physicians are practicing.
Thanks for the message.
Here is the second one that he sent after reviewing some of the Leron data:
Tony-
Thanks for sharing your sentiments.
I knew hydroxychloroquine and azithromycin was ineffective when it first came out and many of my colleagues said the same thing. But they were pressured to give it because they felt that had to give something.
Remdesivir and tocilizumab have been given last several weeks and they are not effective. In fact many of our sickest COVID patients have liver damage from the RANTES induced cytokine storm. So they can’t get remdesivir and tocilizumab because of the liver damage! Doctors then are left with nothing and many refuse to consider Leronlimab. They say we don’t have data but there is knowledge from the HIV trials which are on the NIH page! If not Leronlimab, then what do you propose? ‘Supportive management’. That means cross our fingers and pray the patient doesn’t die!!!
Doctor’s have become technicians and stopped being physicians. ARDS: Low tidal volume, FiO2 of 70%, increase the PEEP, do some proning. That is what their checklist says! And when it fails, start sweating and hope the patient dies quickly or they make a quick recover!
Unfortunately many of my colleagues practice reactive medicine instead of being proactive! We are at war with this virus and during any war deception is key! We have to anticipate the virus next move and have our defenses up and ready! Instead we are CHASING the virus and playing the war on ITS terms! If this were a game, that would be one thing. But people are dying!!! And my friends and colleagues are dying!!! That’s at stake and when I have looked at the raw data (Dr. Lalezari has shared with me the UCLA and Montefiore data)- it is not the magic drug but it works better than anything else we have right now.
So release LERONLIMAB and save our loved ones, friends, and communities!
I just spend most of my nonclinical time fighting these obstinate doctors but I’ll keep fighting for my patients!
Read this and make your own judgements. I choose to trust doctors I know, etc. rather than some clown like Adam FF who's agenda is to further himself rather than putting his life on the line taking care of these patients.
Here is the advanced copy of Patterson's paper. It will be interesting to see if the MSM buries this after it's officially published. Again, a lot of the folks who say they want to help with this are a hell of lot more intersted in lining their own pockets than doing what's right for patients and caregivers. It will be interesting to see if the SA editors allow this to be published. it's one thing for politicians to have pay to play to hand out money for infrastructure, etc.; it's another thing to use pay to play to force doctors to use a drug on these patients that does not work. That's a totally new rubicon."

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Nasdaq Tumbles: AI Hardware Pulls Markets Down

Updated Category News Views 95

Wall Street's Slide Fueled by AI Nerves The markets got a real jolt on Monday, sending Nasdaq down 2.5% thanks to a sharp dip in AI hardware stocks. Tech tickers tied to artificial intelligence were at the core of a sell-off, knocking the S&P 500 down 1.92% alongside it. Investors are on edge, and it’s not just the weather—it's a real shake-up driven by policy moves...

Continue Reading
Chicago Auto Show: Run & Explore Indoors This February

Updated Category News Views 188

Nobody’s thinking about running laps when they walk into a colossal auto show, but the Chicago Auto Show isn't letting the pedal ease off the gas. Swing by on February 14, folks, for something not typically seen on the floors of McCormick Place. Run participants have got one hour to log as many miles as they can on the 2.4-mile loop right inside the show. Why a Running...

Continue Reading
Intel Faces Class Action Over Alleged Securities Fraud

Updated Category News Views 122

Intel's Legal Predicament: Decoding the Lawsuit Saddle up, folks, because Intel (NASDAQ: INTC) has found itself tangled in legal vines again. This ain't their first rodeo, and probably won't be their last. We're looking at a hefty class action lawsuit rallying on claims that Intel misled investors with optimistic yarns about their health. SBS Law, waving the litigation...

Continue Reading
Luxury Villa Cashback Offers Entice Travelers in November

Updated Category News Views 164

A November Bonanza for Villa Bookings Who doesn't love having a few extra bucks in their pocket, especially when they come with the allure of luxury travel? Villas of Distinction is rolling out what they call a 'November Cashback Offer,' and for those with the wallet—and wanderlust—to match, it could be a tempting proposition. Hanging the bait of up to $2,000 cashback...

Continue Reading
S&P Global's Bold $2 Billion Debt Offering Details

Updated Category News Views 80

Drilling Down into S&P Global's Debt Move S&P Global's throwing its hat in the ring with a colossal $2 billion debt offering. Now, they aren't just setting it on the table — they're notably carving it up into three chunks. You’ve got $750 million at 5.600% that comes due in 2031, $600 million at 5.800% for 2034, and $650 million at a 6.000% rate maturing in 2036....

Continue Reading
LA Auto Show 2026: Thrills, Games, and Cars Galore

Updated Category News Views 53

A Family Day Like No Other at the LA Auto Show Kicking into gear this November, the 2026 Los Angeles Auto Show puts the pedal to the metal for families seeking a full day of fun without breaking the bank. We're talking about 10 solid days where auto-mania meshes with interactive experiences, all nestled in the Los Angeles Convention Center. Whether you're a gearhead or a...

Continue Reading
IP Lawyer Chris Henry Returns to Latham: A Game Changer

Updated Category News Views 202

Welcome Home, Chris Henry! Folks, here's a headline that's making waves in the IP litigation water: Chris Henry has returned to Latham & Watkins, taking his place as a heavyweight partner in their Boston office. Now, if you're not deeply entangled in the world of high-stakes intellectual property (IP) disputes, you might shrug. But for tech companies embroiled in patent...

Continue Reading
Lear Gears Up for Goldman Sachs Event Spotlight

Updated Category News Views 132

Lear Prepares for the Big Stage in London Autumn leaves and industry insights are falling in full swing as Lear Corporation gets its ducks in a row for the upcoming Goldman Sachs 18th Annual Industrials & Autos Week. Kicking off on December 3, 2026, this gathering in London isn't just another checkbox on their corporate calendar—it's a prime moment in the spotlight....

Continue Reading
Paris Baguette Expands U.S. Presence with New Georgia Café

Updated Category News Views 163

Café Culture Meets Expansion Chase You ever sip a cup of coffee and hear the rustle of opportunity in the steam? That's what's brewing at Paris Baguette with their new opening in Peachtree Corners, Georgia. This isn't just another café setting up shop; it's part of a larger scheme—expanding their sweet slice of the global market pie. Paris Baguette's Georgia Gamble...

Continue Reading
Tenax Class Action: Investors Alley Fight for Redress

Updated Category News Views 149

Tenax Therapeutics in Hot Water Over Drug Trial Results Amidst the ever-unpredictable tides of the pharmaceutical industry, here comes a doozy – Tenax Therapeutics, Inc. is neck-deep in a shareholder lawsuit. If you tossed some money at NASDAQ:TENX anytime between November 13, 2023, and August 7, 2026, you might be feeling the sting of regret, and rightly so. What Went...

Continue Reading

Top 5 Most Recently Viewed Articles

New York Court Upholds Healthcare Rights for Retirees

Updated Category News Views 94

New York Court of Appeals Decision on Retiree Healthcare Rights In a landmark ruling, the New York Court of Appeals determined that the city is required to cover the total cost of the health insurance plans chosen by its retirees. This decision represents a significant win for over 250,000 retired workers and their families seeking to maintain their healthcare benefits....

Continue Reading
Corning's Strategic Path Amid AI Trends and Market Challenges

Updated Category News Views 1824

Corning Incorporated (NYSE: GLW) hit a crossroads back in 2024 as it tried to balance rising AI trends with challenges lurking in traditional markets. Renowned for its expertise in materials science, particularly specialty glass and optical physics, Corning was looking to leverage these trends while facing stiff competition and economic uncertainties. Quarterly...

Continue Reading
Innovating the Future: The Inaugural Global Quantum Forum

Updated Category News Views 274

Inaugural Global Quantum Forum Set to Launch During TechChicago Week The upcoming Global Quantum Forum promises to be a landmark event for the quantum industry, coinciding with the much-anticipated TechChicago Week. This two-day conference is positioned to take place in an exciting environment where innovation meets collaboration. With over 70 distinguished speakers,...

Continue Reading
Oil Prices React to US Supply and Rising Geopolitical Risks

Updated Category News Views 83

Oil Market Overview: Supply Dynamics and Geopolitical Tensions As oil prices faced a dip recently, analysts found that U.S. supply levels play a significant role in shaping market trends. The weekly report reflecting increased U.S. crude and gasoline stocks was a key factor influencing the downturn. Insights on Current Oil Price Performance Brent crude futures for January...

Continue Reading
Senator McConnell's Recent Stock Purchase Insights and Implications

Updated Category News Views 160

Insights into Senator McConnell's Stock Purchase Recently, it has come to public attention that Senator A. Mitchell McConnell, Jr. has made a notable financial move by purchasing stock in Wells Fargo (NYSE: WFC). This purchase, reported to be valued between $1,001 and $15,000, is part of a pattern of trading activity that might have implications for investors and stock...

Continue Reading